The receptor tyrosine kinase HER2 is an oncogene amplified in invasive breast cancer and its overexpression in mammary epithelial cell lines is a strong determinant of a tumorigenic phenotype. Accordingly, HER2-overexpressing mammary tumors are commonly indicative of a poor prognosis in patients. Several quantitative proteomic studies have employed two-dimensional gel electrophoresis in combination with MS/MS, which provides only limited information about the molecular mechanisms underlying HER2/neu signaling. In the present study, we used a SILAC-based approach to compare the proteomic profile of normal breast epithelial cells with that of Her2/neu-overexpressing mammary epithelial cells, isolated from primary mammary tumors arising in mouse mammary tumor virus-Her2/neu transgenic mice. We identified 23 proteins with relevant annotated functions in breast cancer, showing a substantial differential expression. This included overexpression of creatine kinase, retinol-binding protein 1, thymosin 4 and tumor protein D52, which correlated with the tumorigenic phenotype of Her2-overexpressing cells. The differential expression pattern of two genes, gelsolin and retinol binding protein 1, was further validated in normal and tumor tissues. Finally, an in silico analysis of published cancer microarray data sets revealed a 23-gene signature, which can be used to predict the probability of metastasis-free survival in breast cancer patients.
Introduction
Overexpression of growth factor receptors leads to alterations in downstream signal transduction pathways. These signaling alterations cause aberrant changes in cell proliferation rate and cell-cell signaling that lead to genetic instability and transformation of normal cells into tumor cells [1, 2] . The human epidermal growth factor receptor 2 (HER2) is a ligand-independent receptor tyrosine kinase (RTK) used by cells to amplify the signaling cascades from other growth factor receptors [2] . This RTK is highly Abbreviations: MMTV, mouse mammary tumor virus; QTOF, quadrupole TOF; RTK, receptor tyrosine kinase expressed in about 30% of breast cancer cases that are referred to as HER2-positive, and its overexpression is indicative of low survival rates in breast cancers [3, 4] .
HER2 is homologous to the epidermal growth factor receptor (EGFR), also known as HER1. In humans, there are four HER RTK homologues (HER1-4) [2] . They form homo or heterodimers and autophosphorylate a conserved set of tyrosine residues that, in turn, recruit various adaptor proteins. As a result, growth promoting signals are relayed to the nucleus, where immediate-early genes are induced transcriptionally [2] . HER2 is a potent oncogenic kinase, in part because of its ability to dimerize with other members of the HER family of receptors, EGFR, HER3 and HER4, leading to its activation even in the absence of an extracellular ligand [5, 6] . Its overproduction is sufficient to confer a tumorigenic phenotype to an immortalized cell line [7, 8] .
In addition to gene expression profiling studies [9] [10] [11] [12] , various published proteomic studies have been published that have investigated the proteomic profile of either HER2-positive mammary tissues [13] [14] [15] [16] [17] [18] [19] or HER2-expressing cell lines [20] [21] [22] [23] [24] [25] [26] . Here, we report a quantitative proteomics investigation of a Her2-overexpressing epithelial cell line (H6O5), isolated from a primary mammary tumor of mouse mammary tumor virus (MMTV)-Her2/neu transgenic mice. We compared the proteome of H6O5 cells to that of a nontransformed mouse mammary cell line, C127. Our results show upregulation of tumor protein D52, creatine kinase, retinol-binding protein 1 and thymosin 4. Gelsolin 1 and thrombospondin 1 were among the proteins found to be downregulated. Based on a statistical analysis of published microarray data, we show that these proteins may be novel potential biomarkers to predict clinical outcomes of breast cancer patients.
Materials and methods

Establishment of cell lines from tumors of
Her2/neu-transgenic mice
Primary mammary tumors from 6-month-old transgenic mice were removed and rinsed three times in PBS with 100 U/mL penicillin and 100 mg/mL streptomycin. Each tumor was then minced into small pieces (0.5 mm each) with a sterile scalpel and digested in DMEM/F12 medium containing 10 mg/mL human insulin, 1% penicillin/streptomycin and 0.25 g/80 mL of collagenase A in a 371C shaker rocking at 100 rpm for 2-3 h. The cell suspension was then centrifuged at about 1200 Â g for 5 min, and the pellet containing the cells was washed with 20 mL of DMEM/F12 medium containing 20% FBS twice and cultured in DMEM/ F12 medium supplemented with 10% FBS, 10 mg/mL human insulin, 1% penicillin/streptomycin until the cells formed a subconfluent monolayer. A few cell lines derived from independent tumors were obtained. In particular, clone H605 was maintained in culture for 30 passages and well characterized.
Cell growth assays
Cellular growth curves were obtained by plating 1 Â 10 5 cells/well on 6-well plates (Falcon) with DMEM/F12 medium supplemented with 10% FBS, 10 mg/mL human insulin and 1% penicillin/streptomycin. The cells were counted on days 1, 3, 5 and 7. The experiment was repeated three times in duplicate. The doubling time was calculated based on the following formula: Doubling time 5 ln2/((ln (A/Ao)/t), where A 5 cell numbers at time t; Ao 5 initial cell number.
Cell cycle analysis
H605 cells (2 Â 10 5 cells in 2 mL) were seeded into each well of 6-well plates. After 24 h, the cells were trypsinized, washed, resuspended in PBS and fixed in 70% ethanol. Fixed cells were treated with RNAase (0.1 mg/mL) and stained with propidium iodide (40 mg/mL) on ice for 1 h and analyzed on a Becton-Dickson FACScan flow cytometer. The data were analyzed using CellQuest software.
In vivo transplantation analysis of tumorigenicity of H6O5 tumor cells
Tumorigenicity in vivo was assessed by injection of 5 Â 10 5 H6O5 cells into number four mammary glands of MMTVneu transgenic female mice at 4-6 wk of age. Mammary tumor growth was monitored and measured weekly by a calibrator. The tumor sizes were calculated using the following formula: Volume 5 1/2 length Â height 2 . Mammary tumors and lung tissue were harvested from mice bearing tumors for about 60 days. Histological examination was performed as described previously [27] .
Cell culture
We used a two-state SILAC strategy [28] to compare the whole-cell proteome of Her2/neu-overexpressing mammary epithelial cells with that of a normal mammary epithelial cell line C127 (from ATCC) that does not express Her2/neu. In our experimental design, H6O5 cells were cultured in media containing heavy isotope labeled 13 C 6 Arg and 13 C 6 Lys, whereas C127 cells were cultured in medium containing normal light amino acids. A detailed explanation of how the samples were processed is provided as Supporting Information [29] .
Both cell lines, H6O5 and C127, were maintained at 371C and 5% CO 2 , in DMEM supplemented with 10% FBS and Proteomics 2010, 10, 3800-3810 1% penicillin/streptomycin. For large-scale proteomics experiments, 15-cm tissue culture-treated plates were used. Five plates were cultured for each cell line, making a total of ten dishes.
LC-MS/MS
MS/MS analysis of SILAC-labeled peptides was carried out on a quadrupole TOF (QTOF) (QSTAR) or an LTQ-Orbitrap XL mass spectrometer. The methods used for each instrument and the strategy for data analysis and interpretation are provided in detail as Supporting Information [28, 29] .
Quantitative real-time PCR analysis
Quantitative real time RT-PCR analysis was performed to verify the proteomic results. RNA samples were extracted from C127 and H605 cells, normal mouse mammary tissues and primary tumors of MMTV-Her2/neu transgenic mice. Reverse transcription reaction was performed as follows: 1 mg of DNase-treated total RNA, 0.5 mg of anchored oligo(dT)15 primer and 500 mM dNTPs (New England Biolabs) were heated for 5 min at 651C; 1 Â first strand buffer (Invitrogen), 0.01 M DTT and 200 units of Superscript II (Invitrogen) were added, and reverse transcription was carried out, in a 20-mL reaction, for 50 min at 421C and terminated by heating for 15 min at 701C. To assess for potential contamination of solutions, a control containing all reagents, but devoid of RNA, was included. In addition, a control containing all reagents, except the Superscript II, was included for each sample in order to monitor for possible residual genomic DNA in the RNA preparations.
The quantitative RT-PCR was performed using the fluorescent dye SYBR Green Master Mix following standard protocols on an ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA). The data were first analyzed using the Sequence Detector Software SDS 2.0 (Applied Biosystems). Results were calculated and normalized relative to the GAPDH control by using the Microsoft Excel program. The relative expression values were calculated relative to GAPDH by using the 2 ÀDCT method [29] . The data shown here represent the average of three independent experiments. t-test was performed to show that there are significant differences in the expression of these tested genes among samples.
In silico clinical data analysis
To access the clinical relevance of identified specific genes, we used the list of 23 proteins from Table 1 to perform a statistical analysis of published microarray data. After translating the signature genes into UnigeneIDs, we extracted the gene expression information from published data sets of breast cancer patients [30, 31] and normalized it by samples. We applied the supervised principle component method [32] for testing the performance of the proposed gene set. The principal component of this data set was extracted and used to derive a regression model to predict the survival time from microarray expressions of our biomarker genes. The samples were then divided into highrisk and low-risk groups by comparing to their median survival time. The p-values were calculated using the logrank test, and differences were considered statistically significant at po0.05.
Results and discussion
Cellular characterization of H6O5 cells
The use of a conditionally induced Her2/neu transgenic mouse model has been used previously in two proteomicsbased, biomarker discovery projects [17, 20] . The proteomics strategy in these papers is based on label-free quantitation of protein/peptide ratios [17, 20] . In this study, we used SILAC proteomics to characterize a cell line derived from primary tumors arising in MMTV-Her2/neu transgenic mice. When maintained in culture, H6O5 cells are polygonal and exhibit an epithelial-like morphology (Fig. 1A) . When cultured in DMEM/F12 medium supplemented with 10% BCS and 10 mg/mL human insulin, these cells have a population doubling time of 23 h (Fig. 1B) . Cell cycle analysis under these conditions shows that 65.1% of the cells were in G1 phase, 10.4% in the S phase and 24.1% in G2/M phase (Fig. 1C) .
To investigate whether the malignant potential was still maintained in the H6O5 cell line, 5 Â 10 5 cells were injected into mammary glands of MMTV-Her2/neu transgenic mice. The tumors arose as solid masses that became palpable after about 10 days post inoculation and grew rapidly (Fig. 1D) . At 60 days post inoculation, the animals were sacrificed and tumors were harvested. A histopathological analysis revealed that the morphology of the grafted tumors was comparable to that of the primary mammary adenocarcinomas arising in MMTV-neu transgenic mice (Fig. 1E) . In addition, we found that six out of eight mice developed lung metastases. However, no metastatic lesions were detected in other organs of these transplanted mice including brain, liver or bone. These results are in agreement with previous studies indicating that MMTV-Her2/neu transgenic mice only develop lung metastases [33] .
SILAC-based quantitative proteomics of H6O5 cells
We performed a two-state SILAC experiment [28] in which H6O5 cells were labeled by growing in heavy amino acid containing medium and their proteomic profile was compared with that of C127 cells grown in light amino acid containing medium ( Fig. 2A) . A total of 501 unique proteins were identified and quantitated from duplicate experiments. The first sample set was analyzed on a QTOF mass spectrometer (QSTAR) and resulted in identification of 220 proteins. The other sample set was analyzed on an LTQOrbitrap XL mass spectrometer and resulted in 415 proteins. By comparing the results obtained from the two instruments, we found an overlap of 115 proteins (Fig. 2B) . Additionally, the common proteins detected in both experiments exhibited significant correlation between the two SILAC ratios (r40.7) (Fig. 2C) . Two Supporting Information files contain the list of peptides and the corresponding proteins identified with the QSTAR and the LTQOrbitrap instruments are provided as Supporting Information. Data are also provided about the relative protein levels obtained from their SILAC-derived values. Supporting the notion that equal amounts of C127 and H6O5 cells were mixed proportionately for proteomic analysis, we found that the large majority of proteins had H/L ratios ranging from 0.5 to 2.0 ( Fig. 2C and Supporting Information combined list of proteins and ratios).
Functional classification of the proteins identified
We next classified the identified proteins based on available gene ontology and protein function databases. For this we used the PubMed database from the National Center for Biotechnology Information and several bioinformatics and proteomics resources, including the Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/), the Universal Protein Resource (UniProt) (http://www.uniprot.org), the Expert Protein Analysis System (EXPASY) Proteomics Server (http://ca.expasy.org), and the Gene Ontology project (http://www.geneontology.org/index.shtml). The proteins identified by proteomic analysis were classified into nine categories (protein classification in Supporting Information): (i) membrane and cytoskeleton; (ii) metabolism; (iii) gene expression; (iv) ribosome; (v) ATP hydrolysis and chaperone; (vi) redox homeostasis; (vii) proteasome and proteases; (viii) signaling cascades; and (ix) undetermined function (protein classification in Supporting Information and Supporting Information Fig. 1) .
To illustrate the quality of the protein identifications reported, we present the MS and MS/MS spectra of four selected proteins from the data obtained from the LTQOrbitrap mass spectrometer (Fig. 3) . We used a threefold change in heavy/light (H/L) SILAC ratios as a cut-off to define that a protein had a significant SILAC ratio. From the annotated function classification and the SILAC ratios obtained, we selected a list of relevant proteins with respect to tumor biology, most of which had significant changes in SILAC ratios on at least one of the instruments ( Table 1) . The protein profile obtained after manual curation of the data (Supporting Information Fig. 1 Table 1 , explains the ability of H6O5 cells to form solid tumors when grafted onto mice (Fig. 1D) . In brief, H6O5 cells were found to overexpress thymosin 4, an actin-binding protein previously described as having a role in angiogenesis [34, 35] , while having low protein levels of thrombospondin 1, an angiogenesis inhibitor, that binds to proteins on the cell surface, thereby modulating cell motility and cell adhesion events [36, 37] .
We analyzed the SILAC sample on a QTOF and an LTQOrbitrap mass spectrometer in order to obtain a pair of technical replicates obtained. Despite the overall good correlation in the SILAC ratios derived from the two different instruments (r40.7), we found some variability in the values obtained for the proteins that showed a significant SILAC-ratio change (Table 1) . Such variability was more pronounced in those ratios with pronounced SILAC changes, such as retinol-binding protein 1 (Table 1) , and was minimal in those proteins with a 1:1 ratio, explaining why the overall correlation in SILAC values obtained from two different instruments was good.
An important aspect of our results is that the patterns of downregulation or upregulation in the proteins identified by the two instruments remained constant, despite the differences in the relative SILAC ratios (Table 1) . Furthermore, the variability observed is not unusual and rather highlights the importance validating the relative quantitative values obtained in discovery-based shot-gun proteomics experiments, such as the ones reported here.
Identification of novel biomarkers
To corroborate our quantitative proteomic results, we confirmed all proteins listed in Table 1 at the mRNA level by quantitative RT-PCR in H6O5 and C127 cells. The relative mRNA expression levels in H605 cells versus C127 cells are listed in Table 1 and several PCR products were run on a 1% agarose gel as shown in Fig. 4A . Estimating mRNA levels by RT-PCR is a straightforward strategy in comparison to the Western blot-based validation of proteins for which in many cases a specific antibody is not available. Our results show that 490% of the mRNA values (21 out of 23 genes) correlated with the SILAC-based protein ratios.
An exception was in the case of pyruvate kinase and ribosomal protein L35 that were found to be downregulated in our SILAC experiments, but upregulated at mRNA level in H605 cells by quantitative PCR analysis. A simple explanation to this discrepancy in our results would be incorrect assignment of peptides to these two proteins. At least in the case of pyruvate kinase, this is highly unlikely because its identification score and the number of peptides observed were amongst the highest. Another possibility is that protein levels are indeed lower due to degradation via N2  N3  N4  N5  T1  T2  T3  T4  T5  T6  T7  T8  T9  T10  Relative mRNA level   Gelsolin   0   2   4   6   8   10   N1  N2  N3  N4  N5  T1  T2  T3  T4  T5  T6  T7  T8  T9  T10  Relative mRNA proteases or ubiquitin-mediated protein turnover. Thus, it is possible that HER2 over-expressed in H6O5 cells induces the degradation of certain proteins such as L35 and pyruvate kinase. Regardless of the explanation to this discrepancy, the occurrence of disparate relative values in mRNA and protein levels is not surprising, but rather reflects the intricate post-transcriptional regulation path followed by an mRNA transcript before it gets translated to produce a protein.
Next, we selected two functionally relevant candidate genes, gelsolin 1, which was downregulated and retinolbinding protein 1, which was upregulated, to further validate their expression patterns in primary tumors. Gelsolin 1, an actin-binding protein regulated by calcium, is commonly downregulated in invasive breast carcinoma and is thus a negative prognostic factor in HER-2-positive EGFR-positive breast cancers [38, 39] . Furthermore, an extracellular form of this protein has been identified as downregulated in conditioned medium of pancreatic cancer cell cultures [40] . Cellular retinol-binding protein 1, on the other hand, regulates the bioavailability of retinol/vitamin A by preventing the action of retinol degrading enzymes [41] . A study in endometrial carcinoma has shown that the levels of retinol-binding protein 1 inversely correlated with tumor grade progression [41] .
We used quantitative real-time RT-PCR assay to determine the relative expression levels of gelsolin 1 and retinolbinding protein 1 in normal mammary gland tissues and Her2/neu-induced primary tumors ( Fig. 4C and D) . Consistent with the quantitative proteomic profile, gelsolin expression was significantly downregulated in tumors while retinol-binding protein 1 expression was upregulated (Student's t-test, p valueo0.05).
To further evaluate the clinical relevance of the identified proteins, we used the list of 23 proteins from Table 1 to perform a statistical analysis of published microarray data [30, 31] . Using UnigeneIDs of the corresponding genes, we extracted the gene expression information from published data sets of breast cancer patients [30, 31] . We applied a supervised principle component method to test the performance of this set of genes [26] . The principal component of this data set was extracted and used to derive a regression model to predict the survival time from expression levels of this set of genes in the microarray data set. The samples were then divided into high-risk and low-risk groups by comparing their median survival time. Our analysis revealed that the 23-gene mRNA expression signature could be used to predict the probability of metastasis-free survival in breast cancer patients with statistical confidence (Fig. 5) . The statistical analysis using two microarray data sets from two independent groups showed very similar results, indicating that the quantitative protein profiling that we present here has clinical relevance and could be used to develop a novel biomarker signature in HER2/neu-positive breast cancer.
In this study, we have used an integrative proteomic and genomic analysis to discover novel biomarkers in HER2/ neu-positive breast cancer. HER2/neu-positive breast cancer is generally associated with particular aggressiveness, tumor recurrence, enhanced metastasis, induced chemotherapy resistance and worse prognosis [42] . Both genomic and proteomic approaches have been used to profile the HER2-positive breast cancers and cell lines with the common goal to identify novel biomarkers. The use of a conditionally induced Her2/neu transgenic mouse model has been used previously in two proteomics-based, biomarker discovery projects [13, 17] . The proteomics strategy, while different in these reports, is based on labelfree quantitation of protein/peptide ratios [18] . In the first case a novel statistical algorithm was applied to identify proteins with a relevant protein ratio that were further validated by multiple reaction monitoring targeted-MS [17] . Kaplan-Meier analysis was performed to predict the probability of metastasis-free survival using published microarray data sets. (A) Microarray data set from Wang group [30] . This data set includes 286 lymph node-negative breast cancer patients who received no adjuvant treatment when clinical samples were collected. (B) Microarray data set from van de Vijver group [31] . A total of 295 patients had stage I or II breast cancer and were younger than 53 years; 151 had lymph-nodenegative disease and 144 had lymph-node-positive disease. X-axis represents time of survival. Y-axis represents the probability of metastasis-free survival. MFS, metastasis-free survival.
The most recent of these reports follows up on the aforementioned publication, but uses a custom-built database to identify novel splicing isoforms with a potential as tumor biomarkers [18] . Overall, these and other proteomic strategies offer unique and rather complimentary avenues for biomarker discovery in mammary tumors [13, [17] [18] [19] .
Several studies have reported the mRNA expression profiles of Her2-positive tumors from microarray analysis [43, 44] . However, validation of the long lists of biomarker candidates identified using either proteomic or genomic approaches is challenging. Conventional validation assays such as RT-PCR, ELISA and Western blots are prohibitively resource and time-intensive [45] . To relieve the bottleneck between the discovery and validation phrase, efforts are being made to integrate both proteomic and genomic platforms to discover biomarkers [24, 46] . In line with these efforts, we first used a SILAC proteomic approach to identify differentially expressed proteins in Her2/neu-positive cells, followed by validation at the mRNA level and in silico analysis of published microarray data. This integrative strategy allowed us to identify a 23-gene signature for prediction of clinical outcome of breast cancers. This study demonstrates how the integration of proteomic and genomic gene expression data may prove useful in accelerating cancer biomarker discovery.
Concluding remarks
In this report, we describe the cellular and proteomic characterization of H6O5, which is a Her2/neu positive cell line derived from a spontaneous tumor arising in Her2/neu transgenic mice. Upon confirming that H6O5 cells are tumorigenic when grafted onto mice, we used SILAC quantitative proteomics to establish a protein signature of these cells by manual curation of the literature and gene ontology databases. We found that the protein profile obtained was consistent with the tumorigenic phenotype of H6O5 cells. We next validated mRNA expression patterns of a short list of functionally relevant proteins from Table 1 . We performed this analysis in the two cell lines, H6O5 and C127, and additionally in primary Her2/neu mammary tumors. Further statistical analysis of published cancer microarray data sets indicated that the mRNA expression pattern of a 23-gene signature correlates with clinical outcome in breast cancer patients. We therefore conclude that these proteins may serve as novel biomarkers in breast cancer patients.
